# US 2022/0088185 A1 · Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088185 A1
- Document ID: US20220088185A1
- Status: Published application
- Kind: A1
- Application number: 17/420,529
- Filed: 2020-01-03
- Published: 2022-03-24
- Earliest claimed: 2014-03-03
- Assignees: Albert Einstein College of Medicine
- Applicants: Albert Einstein College of Medicine
- Inventors: Betsy HEROLD; William JACOBS, JR.; Pablo A. GONZALEZ-MUNOZ; Christopher PETRO
- Web page: https://patentgrep.com/patent/US20220088185A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/12: Viral antigens
- A61P 31/22: for herpes viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- C12N 2710/16621: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N 2710/16662: by genetic engineering
- C12N 2710/16671: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.

## Claims

### Claim 1

A method of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising effectuating passive transfer to the first subject of an amount of a product from a pregnant female immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises antibodies induced thereby, effective to elicit an immune response against an HSV-2 and/or HSV-1 infection in the first subject, wherein the first subject is a fetus or neonate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the product comprises serum of the pregnant female.

### Claim 3 (depends on 1)

The method of claim 1, wherein the product comprises breast milk of the pregnant female.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first subject is a fetus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first subject is a neonate.

### Claim 6 (depends on 5)

The method of claim 5, wherein the first subject is born from a second subject.

### Claim 7 (depends on 4)

The method of claim 4, wherein the pregnant female is pregnant with the fetus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first subject and the pregnant female are human.

### Claim 9 (depends on 1)

The method of claim 1, wherein the product comprises antibodies elicited by immunization of the pregnant female with the HSV-2 having the deletion.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method elicits an immune response in the first subject against an HSV-2.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method elicits an immune response in the first subject against an HSV-1.

### Claim 12 (depends on 1)

The method of claim 1, wherein the product further comprises an immunological adjuvant.

### Claim 13 (depends on 12)

The method of claim 12, wherein the product further comprises an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D.

### Claim 14

A method of inhibiting a perinatal HSV-1 and/or HSV-2 infection in a neonate comprising administering to a female pregnant with a fetus which will become the neonate an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit a perinatal HSV-1 and/or HSV-2 infection in a neonate.

### Claim 15

A method of inhibiting HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate comprising administering to the mother an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate.

### Claim 16 (depends on 15)

The method of claim 15, wherein the mother is pregnant with a fetus which will become the neonate.

### Claim 17 (depends on 14)

The method of claim 14, wherein the HSV-1 infection or HSV-1 viral dissemination is inhibited.

### Claim 18 (depends on 14)

The method of claim 14, wherein the HSV-2 infection or HSV-2 viral dissemination is inhibited.

### Claim 19 (depends on 1)

The method of claim 1, wherein an immune response is elicited against HSV-1.

### Claim 20 (depends on 1)

The method of claim 1, wherein an immune response is elicited against HSV-2.

### Claim 21 (depends on 1)

The method of claim 1, wherein the complementing cell is a VD60 cell.

### Claim 22 (depends on 1)

The method of claim 1, wherein the pregnant female, the mother, or the second subject is seronegative for HSV-1, seronegative for HSV-2, or seronegative for both HSV-1 and HSV-2.

### Claim 23 (depends on 1)

The method of claim 1, wherein the pregnant female or the mother is subcutaneously administered the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pregnant female or the mother is administered a subcutaneous boost dose of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof after an initial subcutaneous administration of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene.
